pages:
-
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease
-
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)
-
A Phase 2b, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Multicenter Study of HTX-019 as Treatment for Postoperative Nausea and Vomiting Following Failed Antiemetic Prophylaxis
-
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome
-
A PHASE 2b, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH
-
A phase 2b/3 Randomized Clinical Trial of Clazakizumab in Patients with End Stage Kidney Disease Undergoing Dialysis
-
A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
-
A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis
Fellowships, Supported Research, and Other Grants
-
A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA
-
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on l Therapy for Benign Prostatic Hyperplasia (BPH)
-
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2
-
A Phase 3 Multi-center Randomized Open-Label Study of Carbavance (Meropenem/PRX7009) Versus Best Available Therapy in Subjects with Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
-
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma
-
A Phase 3 Multinational, Randomized, Double-Blind, Placebo Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP 9001 in Subjects With Duchenne Muscular Dystrophy" ("Study"); Sarepta Protocol Number SRP-9001-301
-
A Phase 3 Open Label Multicenter Study of the Safety & Efficacy of Brincidofovir CMX001 in the Treatment of Early versus Late Adenovirus Infection. Chimerix Study CMX001-304
-
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
-
A PHASE 3 OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE
-
A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of
pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
-
A phase 3 pivotal study (118161/118169) and open-label extension (118163) to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects and associated pr
-
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
-
A Phase 3 prospective, randomized, multicenter, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-Matched, living donor kidney transplants
-
A Phase 3 Randomized double blined placebo controlled study to evaluate the efficacy and safety of GS-5745 conbimed with mFOLFAX6 as first line treatment in patients with advanced gastric or gastroeso
-
A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole
-
A Phase 3 randomized placebo contolled parellel-group multicenter double blined study to evaluate the efficacy and safetyof Telotristat Etiprate
-
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T
cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and
Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd)
-
A phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular Rosacea
Fellowships, Supported Research, and Other Grants
-
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+)
-
A Phase 3 Randomized, Double-Blinded Study Comparing Twice Daily Tacrolimus Cream 0.3% versus Cream Vehicle in the Treatment of Atopic Dermatitis in Pediatric Subjects
Fellowships, Supported Research, and Other Grants
-
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients with ocular Graft-vs-Host Disease (oGVHD)
pages: